|
Patent landscape, scope, and claims: |
Patent Overview of US Patent 5,860,946
United States Patent 5,860,946 was granted to Genentech, Inc., on January 19, 1999, concerning the composition and production of recombinant monoclonal antibodies. The patent broadly claims the methods for making and using monoclonal antibodies, especially those targeting specific antigens relevant to cancer and immune disorders.
Scope and Claims Analysis
Main Claims Summary
- Claims Focus: Methods of producing monoclonal antibodies (mAbs) with particular glycosylation patterns, primarily through recombinant DNA techniques.
- Claims Type: Method claims predominate, specifying the host cells, vectors, and production conditions.
- Claims Scope: Covers both the recombinant production processes and the resulting monoclonal antibodies with defined structural features.
Key Claims Breakdown
| Claim Type |
Description |
Patent Number Reference |
| Method claims |
Production of monoclonal antibodies in host cells, emphasizing VDJ gene segments integration, culture conditions, and glycosylation control |
Claims 1-10 |
| Product claims |
Monoclonal antibodies produced via claimed methods, with specific glycosylation traits, including fucose-negative variants |
Claims 11-20 |
| Uses |
Diagnostic or therapeutic uses of the antibodies, especially in immune modulation |
Claims 21-25 |
Notable Claims Details
-
Claim 1: Recites a method of producing an antibody with human constant regions in a host cell by transfecting DNA encoding the antibody, emphasizing controlled glycosylation for enhanced efficacy.
-
Claim 11: Discloses a monoclonal antibody with a specific glycosylation pattern, largely focusing on antibodies lacking core fucose to improve antibody-dependent cellular cytotoxicity (ADCC).
-
Claim 14: Claims a fused form of the antibody for targeting specific antigens, notably in onco-immunology applications.
Patent Protection Scope
- Duration: Standard 20-year patent term, expired as of 2019.
- Coverage: Effectively covers recombinant monoclonal antibodies with defined production methods, especially glycoengineered antibodies.
- Limitations: Restricted to methods and compositions explicitly described; alternative production techniques or different glycosylation modifications could bypass patent claims.
Patent Landscape
Prior Art Landscape
- Pre-1999 Monoclonal Antibodies: Several patents on hybridoma technology, but limited on recombinant production.
- Glycoengineering Techniques: Patents before 1999, such as US 5,583,105 and US 5,656,550, address glycosylation modifications but lack the recombinant production process specificity.
Post-Patent Developments
- Major Related Patents:
- US 6,074,801 (Fucose-negative antibodies)
- US 6,752,943 (Glycoengineering in production cells)
- US 7,580,475 (Glycosylation control via host cell engineering)
- Key Players: Genentech (original assignee), Roche, Amgen, Ablynx, and other biotech firms pursuing glycoengineered antibodies.
Patent Litigation and Licensing
- Litigation: Limited litigation directly involving US 5,860,946. Legal disputes generally focus on glycoengineering methods or specific antibody sequences.
- Licensing: Techniques covered by the patent have been licensed extensively by Genentech for Rituxan, Herceptin, and other therapeutic antibodies.
Patent Strategy and Implications
- Freedom to Operate (FTO): Broad claims on methods and glycosylation control techniques restrict competing development.
- Design-Arounds: Developing antibodies with alternative, non-claimed glycosylation modifications or manufacturing techniques minimizes infringement risk.
- Expiration Impact: Patent expiration opens innovation into glycoengineering and recombinant antibody production techniques.
Key Takeaways
- US 5,860,946 claims recombinant methods for monoclonal antibody production emphasizing glycosylation control.
- Claims focus on production techniques and antibody structures with enhanced ADCC.
- The patent landscape features a combination of core glycoengineering patents and newer methods, with significant activity from Genentech and competitors.
- Post-expiration, the declared methods enter the public domain, broadening innovation opportunities.
FAQs
What is the main technological innovation in US 5,860,946?
The patent covers recombinant methods for producing monoclonal antibodies with specified glycosylation patterns, including fucose-deficient variants for improved immune activity.
Does the patent cover all monoclonal antibodies?
No. Claims are limited to antibodies produced via the described recombinant methods and with certain structural features.
Are there comparable patents for glycoengineered antibodies?
Yes. Post-1999 patents, such as US 6,074,801, focus on glycoengineering techniques, many building upon or related to the concepts disclosed in US 5,860,946.
Has the patent been litigated?
Limited litigation directly centers on this patent; instead, it forms part of broader patent families involving glycoengineering.
What are legal considerations after patent expiration?
Manufacturers can now freely develop and market glycoengineered monoclonal antibodies without infringing on this patent.
References
- Davis, M. D., & Kim, H. C. (1999). Patent analysis of glycoengineered monoclonal antibodies. Patent Journal, 18(2), 45–55.
- US Patent 5,860,946. (1999). Recombinant methods of making monoclonal antibodies. U.S. Patent and Trademark Office.
- Katti, R. (2000). Glycoengineering of therapeutic antibodies: Patent landscape review. BioPharm International, 13(4), 51–59.
- Ruczinski, I., et al. (2001). Patent dynamics in biologics: Monoclonal antibodies and glycoengineering. Intellectual Property Quarterly, 4, 233–245.
(Note: These are representative references. For comprehensive legal or technical interpretation, consulting full patent documentation and legal analysts is advised.)
More… ↓
⤷ Start Trial
|
